newsfilter
← Latest News
Business Wire·

Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights

SRTS
  • Sensus Healthcare reported Q2 2026 revenues of $2.3 million, a 68.5% decrease from $7.3 million in Q2 2025.
  • The revenue decline resulted from selling only 11 units compared to 19 in the prior year, including no sales to a major U.S. customer.
  • Revenue recognition for eight purchased units was shifted to Q3 2026 due to financing approval timing delays.
  • Gross profit decreased to $0.8 million from $2.9 million, driven by product mix changes & upfront costs for Fair Deal Agreements.
  • Net loss widened to $8.7 million ($0.53 per share) from $1.0 million ($0.06 per share) in the prior year period.
  • Adjusted EBITDA for the quarter was negative $3.0 million, an increase from negative $1.8 million in Q2 2025.
  • General & administrative expenses fell to $1.8 million, while selling, marketing & R&D expenses also decreased year-over-year.
  • Cash, restricted cash & cash equivalents stood at $15.2 million as of June 30, 2026, with no outstanding borrowings.
  • CMS proposed a 26% increase in the hospital-based SRT delivery code, potentially improving provider economics.
  • Customer adoption accelerated through expanded engagement with independent practices, physician groups, & health systems.
  • International commercial activity expanded in Asia-Pacific markets, including Australia & New Zealand.
  • Active website users increased 153% year-over-year, reflecting growing physician engagement.
  • Management anticipates strong performance in the second half of 2026 & remains focused on five strategic priorities.
  • Sensus Healthcare operates as a global developer of non-invasive superficial radiotherapy (SRT) treatments for skin conditions.